Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging
The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of l...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Demétrio de Souza França, Paula [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020transfer abstract |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time - Michaud, Jason E. ELSEVIER, 2023, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:84 ; year:2020 ; pages:80-87 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.nucmedbio.2020.01.004 |
|---|
| Katalog-ID: |
ELV050370596 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV050370596 | ||
| 003 | DE-627 | ||
| 005 | 20230626030340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200625s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nucmedbio.2020.01.004 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica |
| 035 | |a (DE-627)ELV050370596 | ||
| 035 | |a (ELSEVIER)S0969-8051(19)30544-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.88 |2 bkl | ||
| 100 | 1 | |a Demétrio de Souza França, Paula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| 264 | 1 | |c 2020transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. | ||
| 520 | |a The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. | ||
| 700 | 1 | |a Roberts, Sheryl |4 oth | |
| 700 | 1 | |a Kossatz, Susanne |4 oth | |
| 700 | 1 | |a Guru, Navjot |4 oth | |
| 700 | 1 | |a Mason, Christian |4 oth | |
| 700 | 1 | |a Zanoni, Daniella Karassawa |4 oth | |
| 700 | 1 | |a Abrahão, Marcio |4 oth | |
| 700 | 1 | |a Schöder, Heiko |4 oth | |
| 700 | 1 | |a Ganly, Ian |4 oth | |
| 700 | 1 | |a Patel, Snehal G. |4 oth | |
| 700 | 1 | |a Reiner, Thomas |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Michaud, Jason E. ELSEVIER |t Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |d 2023 |g Amsterdam [u.a.] |w (DE-627)ELV010596976 |
| 773 | 1 | 8 | |g volume:84 |g year:2020 |g pages:80-87 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.nucmedbio.2020.01.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.88 |j Urologie |j Nephrologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 84 |j 2020 |h 80-87 |g 8 | ||
| author_variant |
d s f p d dsfp dsfpd |
|---|---|
| matchkey_str |
demtriodesouzafranapaularobertssherylkos:2020----:loie8aeeplapioeoyeaeihbtrsptnillentvt2ex28furdlcspstoe |
| hierarchy_sort_str |
2020transfer abstract |
| bklnumber |
44.88 |
| publishDate |
2020 |
| allfields |
10.1016/j.nucmedbio.2020.01.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica (DE-627)ELV050370596 (ELSEVIER)S0969-8051(19)30544-X DE-627 ger DE-627 rakwb eng 610 VZ 44.88 bkl Demétrio de Souza França, Paula verfasserin aut Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. Roberts, Sheryl oth Kossatz, Susanne oth Guru, Navjot oth Mason, Christian oth Zanoni, Daniella Karassawa oth Abrahão, Marcio oth Schöder, Heiko oth Ganly, Ian oth Patel, Snehal G. oth Reiner, Thomas oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:84 year:2020 pages:80-87 extent:8 https://doi.org/10.1016/j.nucmedbio.2020.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 84 2020 80-87 8 |
| spelling |
10.1016/j.nucmedbio.2020.01.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica (DE-627)ELV050370596 (ELSEVIER)S0969-8051(19)30544-X DE-627 ger DE-627 rakwb eng 610 VZ 44.88 bkl Demétrio de Souza França, Paula verfasserin aut Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. Roberts, Sheryl oth Kossatz, Susanne oth Guru, Navjot oth Mason, Christian oth Zanoni, Daniella Karassawa oth Abrahão, Marcio oth Schöder, Heiko oth Ganly, Ian oth Patel, Snehal G. oth Reiner, Thomas oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:84 year:2020 pages:80-87 extent:8 https://doi.org/10.1016/j.nucmedbio.2020.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 84 2020 80-87 8 |
| allfields_unstemmed |
10.1016/j.nucmedbio.2020.01.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica (DE-627)ELV050370596 (ELSEVIER)S0969-8051(19)30544-X DE-627 ger DE-627 rakwb eng 610 VZ 44.88 bkl Demétrio de Souza França, Paula verfasserin aut Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. Roberts, Sheryl oth Kossatz, Susanne oth Guru, Navjot oth Mason, Christian oth Zanoni, Daniella Karassawa oth Abrahão, Marcio oth Schöder, Heiko oth Ganly, Ian oth Patel, Snehal G. oth Reiner, Thomas oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:84 year:2020 pages:80-87 extent:8 https://doi.org/10.1016/j.nucmedbio.2020.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 84 2020 80-87 8 |
| allfieldsGer |
10.1016/j.nucmedbio.2020.01.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica (DE-627)ELV050370596 (ELSEVIER)S0969-8051(19)30544-X DE-627 ger DE-627 rakwb eng 610 VZ 44.88 bkl Demétrio de Souza França, Paula verfasserin aut Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. Roberts, Sheryl oth Kossatz, Susanne oth Guru, Navjot oth Mason, Christian oth Zanoni, Daniella Karassawa oth Abrahão, Marcio oth Schöder, Heiko oth Ganly, Ian oth Patel, Snehal G. oth Reiner, Thomas oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:84 year:2020 pages:80-87 extent:8 https://doi.org/10.1016/j.nucmedbio.2020.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 84 2020 80-87 8 |
| allfieldsSound |
10.1016/j.nucmedbio.2020.01.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica (DE-627)ELV050370596 (ELSEVIER)S0969-8051(19)30544-X DE-627 ger DE-627 rakwb eng 610 VZ 44.88 bkl Demétrio de Souza França, Paula verfasserin aut Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging 2020transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. Roberts, Sheryl oth Kossatz, Susanne oth Guru, Navjot oth Mason, Christian oth Zanoni, Daniella Karassawa oth Abrahão, Marcio oth Schöder, Heiko oth Ganly, Ian oth Patel, Snehal G. oth Reiner, Thomas oth Enthalten in Elsevier Science Michaud, Jason E. ELSEVIER Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time 2023 Amsterdam [u.a.] (DE-627)ELV010596976 volume:84 year:2020 pages:80-87 extent:8 https://doi.org/10.1016/j.nucmedbio.2020.01.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.88 Urologie Nephrologie VZ AR 84 2020 80-87 8 |
| language |
English |
| source |
Enthalten in Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time Amsterdam [u.a.] volume:84 year:2020 pages:80-87 extent:8 |
| sourceStr |
Enthalten in Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time Amsterdam [u.a.] volume:84 year:2020 pages:80-87 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Urologie Nephrologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| authorswithroles_txt_mv |
Demétrio de Souza França, Paula @@aut@@ Roberts, Sheryl @@oth@@ Kossatz, Susanne @@oth@@ Guru, Navjot @@oth@@ Mason, Christian @@oth@@ Zanoni, Daniella Karassawa @@oth@@ Abrahão, Marcio @@oth@@ Schöder, Heiko @@oth@@ Ganly, Ian @@oth@@ Patel, Snehal G. @@oth@@ Reiner, Thomas @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV010596976 |
| dewey-sort |
3610 |
| id |
ELV050370596 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050370596</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626030340.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200625s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nucmedbio.2020.01.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050370596</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0969-8051(19)30544-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.88</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Demétrio de Souza França, Paula</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roberts, Sheryl</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kossatz, Susanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guru, Navjot</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mason, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zanoni, Daniella Karassawa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abrahão, Marcio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schöder, Heiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ganly, Ian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patel, Snehal G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reiner, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Michaud, Jason E. ELSEVIER</subfield><subfield code="t">Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010596976</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:84</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:80-87</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nucmedbio.2020.01.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.88</subfield><subfield code="j">Urologie</subfield><subfield code="j">Nephrologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">84</subfield><subfield code="j">2020</subfield><subfield code="h">80-87</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| author |
Demétrio de Souza França, Paula |
| spellingShingle |
Demétrio de Souza França, Paula ddc 610 bkl 44.88 Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| authorStr |
Demétrio de Souza França, Paula |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV010596976 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.88 bkl Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| topic |
ddc 610 bkl 44.88 |
| topic_unstemmed |
ddc 610 bkl 44.88 |
| topic_browse |
ddc 610 bkl 44.88 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s r sr s k sk n g ng c m cm d k z dk dkz m a ma h s hs i g ig s g p sg sgp t r tr |
| hierarchy_parent_title |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| hierarchy_parent_id |
ELV010596976 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV010596976 |
| title |
Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| ctrlnum |
(DE-627)ELV050370596 (ELSEVIER)S0969-8051(19)30544-X |
| title_full |
Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| author_sort |
Demétrio de Souza França, Paula |
| journal |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| journalStr |
Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
80 |
| author_browse |
Demétrio de Souza França, Paula |
| container_volume |
84 |
| physical |
8 |
| class |
610 VZ 44.88 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Demétrio de Souza França, Paula |
| doi_str_mv |
10.1016/j.nucmedbio.2020.01.004 |
| dewey-full |
610 |
| title_sort |
fluorine-18 labeled poly (adp-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18f]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| title_auth |
Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| abstract |
The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. |
| abstractGer |
The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. |
| abstract_unstemmed |
The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging |
| url |
https://doi.org/10.1016/j.nucmedbio.2020.01.004 |
| remote_bool |
true |
| author2 |
Roberts, Sheryl Kossatz, Susanne Guru, Navjot Mason, Christian Zanoni, Daniella Karassawa Abrahão, Marcio Schöder, Heiko Ganly, Ian Patel, Snehal G. Reiner, Thomas |
| author2Str |
Roberts, Sheryl Kossatz, Susanne Guru, Navjot Mason, Christian Zanoni, Daniella Karassawa Abrahão, Marcio Schöder, Heiko Ganly, Ian Patel, Snehal G. Reiner, Thomas |
| ppnlink |
ELV010596976 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.nucmedbio.2020.01.004 |
| up_date |
2024-07-06T17:20:40.061Z |
| _version_ |
1803851074176548864 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV050370596</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626030340.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">200625s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.nucmedbio.2020.01.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV050370596</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0969-8051(19)30544-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.88</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Demétrio de Souza França, Paula</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in oral cancer imaging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The evaluation of disease extent and post-therapy surveillance of head and neck cancer using 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) PET is often complicated by physiological uptake in normal tissues of the head and neck region, especially after surgery or radiotherapy. However, irrespective of low positive predictive values, [18F]FDG PET remains the standard of care to stage the disease and monitor recurrences. Here, we report the preclinical use of a targeted poly (ADP-ribose) polymerase1 (PARP1) binding PET tracer, fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([18F]PARPi), as a potential alternative with greater specificity.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roberts, Sheryl</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kossatz, Susanne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guru, Navjot</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mason, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zanoni, Daniella Karassawa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abrahão, Marcio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schöder, Heiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ganly, Ian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patel, Snehal G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reiner, Thomas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Michaud, Jason E. ELSEVIER</subfield><subfield code="t">Inflammatory Expression Profiles in Bladder Exstrophy Smooth Muscle: Normalization Over Time</subfield><subfield code="d">2023</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV010596976</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:84</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:80-87</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.nucmedbio.2020.01.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.88</subfield><subfield code="j">Urologie</subfield><subfield code="j">Nephrologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">84</subfield><subfield code="j">2020</subfield><subfield code="h">80-87</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| score |
7.4012003 |